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Abstract
Background: Lymphocyte Function-Associated Antigen-1 (LFA-1) likely plays a role in the pathogenesis of against
HIV-1 and is known to facilitate cell-to-cell transmission of the virus. A monoclonal antibody specific for LFA-1
(Cytolin
W) was evaluated as a potential therapeutic in pilot studies performed in the mid-1990s. These uncontrolled
human studies suggested that administration of this anti-LFA-1 antibody to HIV-1 infected individuals could provide
a modest benefit by decreasing circulating HIV-1 RNA and increasing CD4+ T cell counts. At the time, it was
proposed that when bound to cytolytic T cells, the antibody inhibited lysis of activated CD4+ T cells. Given the
renewed interest in monoclonal antibody therapy for HIV-1 infected individuals, we investigated possible
mechanisms of action of this antibody in vitro.
Methods: To assess whether this anti-LFA-1 antibody binds to HIV-1, a virus capture assay was performed. Binding
of the antibody to cells was assessed using flow cytometry. Inhibition of HIV-1 replication was determined in
culture by measuring the amount of p24 produced by ELISA. After co-culture of the antibody with peripheral blood
mononuclear cells, supernatants were assayed for cytokines and chemokines using various immunoassays.
Results: Our experiments demonstrate that anti-LFA-1 antibody binds to CCR5 and CXCR4 utilizing strains of HIV-1. It
also binds to CD8+ T cells and dendritic cells. When bound to virus prior to infection, there is no decrease in HIV-1
replication, suggesting it does not directly inhibit viral replication via virus binding. When bound to cells, it does not
inhibit lysis of CD4+ T cells, as was originally hypothesized. Binding to cells does appear to induce the production of a
s o l u b l ef a c t o rt h a ti n h i b i t sH I V - 1r e p l i c a t i o n .W ed e t e r m i ned that this soluble factor was not any of the cytokines or
chemokines with known anti-HIV-1 activity. Further, the antibody does not appear to induce any common immune
modulating cytokines or chemokines.
Conclusions: These results suggest that one possible mechanism of action of this anti-LFA-1 antibody is to inhibit HIV-1
replication via the production of a soluble antiviral factor that is induced upon binding to cells.
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Lymphocyte Function-Associated Antigen-1 (LFA-1,
CD11a/CD18) is a member of the integrin family of ad-
hesion molecules. It is expressed on immune cells and
plays a role in leukocyte trafficking, antigen presentation,
cellular activation, and adhesion of Cytotoxic T lympho-
cytes (CTL) to their targets. In addition to its role in the
immune response, LFA-1 and its ligands are incorporated
into the viral envelope as HIV-1 buds from the cell sur-
face [1]. These proteins facilitate viral synapse formation
and promote cell-to-cell transmission of the virus [2].
Cytolin® is a murine anti-human monoclonal antibody
that binds to LFA-1 (hereafter referred to as LFA-1
MAb). It recognizes an epitope within CD11a known as
S6F1. This epitope is preferentially expressed on CD8+
T cells and can be used to distinguish killer effector cells
from suppressor effector cells [3]. In HIV-1 infected in-
dividuals, CD8+ T cells play a central role in controlling
viral replication by lysing infected cells. It has been
shown that the frequency of CD8+ T cells expressing the
S6F1 epitope is higher in HIV-1 infected individuals
compared to uninfected controls [4,5]. The S6F1+ cell
subset is not expanded in individuals with Epstein Barr
Virus (EBV) infection [6], suggesting this epitope may
play a unique role in the pathogenesis of HIV-1 infection
and is not merely the result of expansion of this cell sub-
set due to chronic viral infection.
It has been hypothesized that LFA-1 MAb could be
used therapeutically to alter the course of HIV-1 infec-
tion. In several small clinical studies [7,8] a reduction in
HIV-1 RNA (range 0.2-1 log10 copies/ml) and a modest
increase in CD4 T cell count (range 70–200 cells/mm
3)
was observed when the antibody was administered to
HIV-1 infected individuals. At the time, investigators hy-
pothesized that LFA-1 MAb improved CD4 T cell counts
by inhibiting the cytolytic effect of CD8+ T cells (CTL)
on activated uninfected CD4+ T cells [7]. This hypoth-
esis was based on in vitro studies that suggested that
CTL killing of activated uninfected CD4+ T cells con-
tributes to CD4+ T cell depletion in HIV-1 infected indi-
viduals [9,10]. This lytic activity was shown to be
abrogated using an antibody specific to LFA-1 [10].
Given the increased interest in monoclonal antibody
therapy in persons with HIV-1 infection, we set out to
determine possible mechanisms of action of LFA-1 MAb.
Results
Patient characteristics
We recruited a cohort of individuals for blood donation
including 12 HIV-1 positive and 13 HIV-1 negative sub-
jects. Blood was collected at multiple time points from
each study subject over a 21-month period. The demo-
graphics and clinical characteristics of the cohort are
summarized in Table 1. The HIV-1 infected subjects in
the cohort were in the asymptomatic phase of infection
and were not on antiretroviral therapy. The mean HIV-1
plasma RNA viral load was 18,495 copies/ml and was
similar over the course of the study (p=0.84, repeated
measures ANOVA). The mean CD4 Tcell count in HIV-1
infected subjects was 661 cells/mm
3, which was slightly
lower than the HIV-1 negative subjects (mean=859 cell/
mm3) and remained relatively unchanged (p=0.76, re-
peated measures ANOVA).
Inhibiting HIV-1 replication via virus binding
Given that LFA-1 can be incorporated into the HIV-1
envelope upon budding, we asked whether LFA-1
MAb could inhibit HIV-1 replication via binding to
virus. To address this, we first performed a virus cap-
ture assay to determine whether LFA-1 MAb could
bind to HIV-1. Undiluted virus stocks representing
both CCR5 utilizing (HIV-SF162, HIV-AC225) and
CXCR4 utilizing (HIV-IIIB) HIV-1 strains were incu-
bated in wells coated with LFA-1 MAb. Captured vi-
rions were then detected using a p24 ELISA. HIV-1
p24 was not detected in control wells containing PBS.
The mean concentration of wells containing LFA-1
MAb was 112 pg/ml for HIV-AC225, 43 pg/ml for
HIV-SF162, and 127 pg/ml for HIV-IIIB. To determine
whether LFA-1 MAb bound one isolate better than an-
other, we normalized this data to the p24 content of each
viral stock (AC225 60,040 pg/ml, SF162 148,986 pg/ml,
IIIB 108,727 pg/ml). As shown in Figure 1A, LFA-1 MAb
captured the primary isolate, HIV-AC225 better than the
other CCR5 utilizing isolate, HIV-SF162, and about the
Table 1 Cohort characteristics
Cohort demographics n=25
Male 72%
Female 28%
Caucasian 72%
African American 12%
Asian 16%
Mean Age (years) 36
Clinical Parameters HIV HIV
Negative Positive
(n=13) (n=12)
Mean HIV Plasma Viral Load at
first visit copies/ml (range)
ND 18,495
(289–85,500)
Mean Absolute CD4 Count at
first visit cells/mm
3 (range)
859 661 NS
(415–1624) (385–1150)
Mean Absolute CD8 Count at
first visit cells/mm
3 (range)
478 1153 p<0.0001
(231–766) (695–2722)
NS, not significant.
ND, not detected.
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interpret these data, we performed a similar assay, in paral-
lel, using a mixture of monoclonal antibodies specific to
HIV-gp120 to capture each viral stock rather than LFA-1
MAb. The gp120-specific antibodies were slightly better at
capturing all three viral isolates. In this case, the amount of
p24 captured was 270 pg/ml for HIV-AC225, 87 pg/ml for
HIV-SF162, and 262 pg/ml for HIV-IIIB. Given that the
virus specific antibodies (anti-gp120) were able to capture
a similar amount of virus as the LFA-1 MAb, we conclude
that LFA-1 MAb binds to virus particles.
We then asked whether HIV-1 replication could be
inhibited in the presence of LFA-1 MAb. The same viral
stocks were incubated with increasing concentrations of
LFA-1 MAb prior to infecting PHA activated CD8-
depleted PBMC. These infection assays were performed
in triplicate using cells from ten of the HIV-1 negative
subjects. As shown in Figure 1B, there was a trend for a
decrease in replication with higher concentrations of
LFA-1 MAb for HIV-IIIB and to a lesser extent HIV-
SF162. However, the mean concentration of p24 was not
significantly different when virus was pre-incubated with
LFA-1 MAb for any of the three viral isolates (p=0.07
for IIIB, p= 0.55 for SF162, p=0.56 for AC225, one way
ANOVA). Although LFA-1 MAb is able to bind to
CXCR4 and CCR5 utilizing strains of HIV-1, this does
not result in the inhibition of viral replication.
Inhibiting HIV replication via cell binding
The S6F1 epitope, to which LFA-1 MAb binds, was
previously shown to be preferentially expressed on
CD8+ T cells [3]. Flow cytometric analysis of PBMC
was used to verify this finding and identify other cell
subsets that LFA-1 MAb binds. PBMC from 10 of the
HIV-1 negative and 11 of the HIV-1 positive subjects
were incubated with LFA-1 MAb and antibodies that
differentiate T cells, B cells, dendritic cells, and mono-
cytes. The percent of LFA-1 MAb positive cells was
highest in the CD8+ T cell subset (mean=19.43 for
HIV-1 negative, mean=38.31 for HIV-1 positive),
followed by dendritic cells (mean=35.46 for HIV-1
negative, mean =25.24 for HIV-1 positive). We identi-
fied very few monocytes (mean=4.4 for HIV-1 nega-
tive, mean=2.5 for HIV-1 positive), CD4+ T cells
(mean=1.2 for HIV-1 negative, mean=1.4 for HIV-1
positive), or B cells (mean =0.4 for HIV-1 negative,
Figure 1 LFA-1 MAb does not directly inhibit HIV replication via binding to virions. (A) A virus capture assay was used to determine
whether LFA-1 MAb binds to HIV-1. Triplicate wells were coated with 5 μg/ml of LFA-1 MAb or PBS as a control. Undiluted virus stocks were then
added to each well and the presence of bound virus was determined using a p24 ELISA. Results are expressed as the concentration of captured
p24 divided by the concentration of p24 in the undiluted virus stock. (B) PHA-activated CD8+ cell depleted PBMC from 10 HIV-1 negative
subjects were infected in triplicate with the same three HIV-1 isolates in the presence of increasing concentrations of LFA-1 MAb. The degree of
HIV-1 replication was determined using a p24 ELISA on the supernatant at day 7. Each dot represents a single subject. The line represents the
mean for each concentration of LFA-1 MAb tested. There was no significant difference in replication in the presence of LFA-1 MAb as compared
to PBS only control for any of the viruses tested.
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MAb (Figure 2). The percent of CD8+ T cells that
bound LFA-1 MAb was significantly higher in HIV-1
positive subjects (p=0.0151, Mann Whitney test) and cor-
related with the absolute CD8+ T cell count (p=0.0011,
Pearson correlation, data not shown). HIV-1 negative and
HIV-1 positive subjects had similar percentages of LFA-1
MAb positive cells in the remaining cell subsets (p=0.08
for dendritic cells, p=0.68 for CD4+ T cells, p=0.22 for
monocytes, p=0.53 for B cells; Mann Whitney test). Given
that the conformation of LFA-1 can change based on the
activation status of a cell, we performed a similar analysis
on cells activated with PMA and Ionomycin prior to cell
surface staining. We found no difference in the mean
frequency of LFA-1 MAb positive cells for any of these
cell subsets when inactivated and activated cells were
compared (p=0.82 for CD8+ Tcells, p=0.62 for dendritic
cells, p=0.53 for monocytes, p=0.71 for CD4+ T cells;
Mann Whitney test; data not shown).
It was initially proposed that LFA-1 MAb could pre-
vent the loss of CD4 Tcells in HIV-1 infected individuals
by inhibiting CTL from lysing activated uninfected CD4+
T cells [7]. To test this hypothesis, activated uninfected
CD4+ target cells were co-cultured with CD4-depleted
PBMC effector cells in the presence and absence of LFA-1
MAb and the amount of cytotoxicity was determined
by flow cytometry. In this assay, target cells are
stained with CFSE to differentiate them from effector
cells and all cells are stained with 7AAD, a viability
dye that specifically stains dead cells. This allows
dead target cells (CFSE+7AAD+cells) to be readily
enumerated. Effector cells from HIV-1 positive
subjects were more cytotoxic than effector cells from
HIV-1 negative subjects, regardless of whether they
were incubated with PBS (p = 0.0115, Mann Whitney
test) or LFA-1 MAb (p=0.0185 LFA-1 MAb, Mann
Whitney test) (Figure 3). In the presence of LFA-1
MAb, the frequency of dead target cells decreased in
cultures from 4 of 10 HIV-1 negative and 5 of 10 HIV-1
positive subjects. However, the mean percent cytotox-
icity was similar in the presence or absence of LFA-1
MAb for both groups (p=0.879 for HIV-1 negative,
p = 0.5286 for HIV-1 positive, paired t test). These data
suggests that LFA-1 MAb does not inhibit CTL killing of
activated uninfected CD4+ T cells. Thus, we were unable
to substantiate the previously hypothesized mechanism
of action [7].
LFA-1 can act as both an adhesion and a signaling pro-
tein [11]. The integrin family to which LFA-1 belongs has
been shown to transmit signals when bound by ligand,
resulting in the production of inflammatory cytokines
[12]. Given that HIV-1 replication is inhibited by several
cytokines and chemokines, we next asked whether, when
bound to cells, LFA-1 MAb induced the production of a
soluble factor that would inhibit HIV-1 replication. To
evaluate this question, PBMC from eight of the HIV-1
positive and six of the HIV-1 negative donors were incu-
bated with increasing concentrations of LFA-1 MAb for
24 hours. The supernatant from these cultures was then
added to a viral replication assay and the degree of HIV-1
Figure 2 LFA-1 MAb binds to CD8+ T cells and dendritic cells.
PBMC from 10 HIV-1 negative (open circles) and 11 HIV-1 positive
subjects (closed circles) were incubated with LFA-1 MAb and
fluorochrome labeled antibodies that differentiated immune cell
subsets then analyzed using flow cytometry. Results are expressed as
the percent of LFA-1 MAb positive cells within each cell subset for
each subject tested. The horizontal line indicates the mean percent
within each subset. The mean percent of CD8+ LFA-1 MAb positive
cells was significantly higher in HIV infected subjects (p= 0.0151,
Mann Whitney test). There was no significant difference in the
percent of LFA-1 MAb positive cells in the remaining cell subsets.
Figure 3 LFA-1 MAb does not inhibit CTL killing of activated
uninfected CD4+ target cells. CD4-depleted PBMC effector
cells from ten HIV-1 negative and ten HIV positive subjects were
co-cultured at a ratio of 25:1 with activated uninfected CFSE
labeled CD4+ target cells and cytotoxicity was determined using
flow cytometry to differentiate 7AAD+(dead) and 7AAD- (live)
target cells. Effector cells from HIV positive subjects were more
cytotoxic (p=0.0115 for PBS, p=0.0185 for LFA-1 MAb, Mann
Whitney test) but the degree of cytotoxicity did not decrease
significantly in the presence of LFA-1 MAb for cells from either
HIV-1 positive or HIV-1 negative subjects (p=0.879 for HIV-1
negative, p=0.5286 for HIV-1 positive, paired t test).
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p24 antigen (Figure 4). As a positive control, culture
media was used in place of supernatant to ensure a pro-
ductive infection (p24= 17,157 pg/ml). There was a sig-
nificant decrease in HIV-1 replication in the presence of
supernatants stimulated by LFA-1 MAb compared to su-
pernatants stimulated with PBS alone (p= 0.0006, one
way ANOVA). Supernatants from five HIV-1 negative
and two HIV-1 positive subjects inhibited replication by
greater than 85% at every concentration of LFA-1 MAb
tested. From these data we conclude that LFA-1 MAb
can induce the production of a soluble antiviral factor. In
the seven other subjects, PBS stimulated control superna-
tants inhibited HIV-1 replication and no further inhibition
was observed when LFA-1 MAb stimulated supernatants
from these subjects were tested, suggesting that cells from
some individuals produce antiviral factors spontaneously
and LFA-1 MAb does not further enhance this production.
Identifying the antiviral soluble factor
Given that PBMC produced the antiviral soluble factor
within 24 hours, we hypothesized that the factor may be
one of the cytokines or chemokines with known anti-
HIV-1 activity [13-15]. We looked for analytes that were
present at higher concentrations in the LFA-1 MAb
treated supernatants than in the PBS treated superna-
tants. Our first set of candidates included the beta
chemokines, MIP1-alpha, MIP1-beta, and RANTES. As
shown in Figure 5A, there was no significant increase in
any of these chemokines in the presence of LFA-1 MAb
(p=0.16 for MIP1-alpha, p=0.34 for MIP1-beta, p=0.28
for RANTES, Wilcoxon sign rank test). We next tested
the supernatants for alpha-defensins (HNP 1, 2, and 3)
and Interferon-alpha (IFN-alpha). The concentration of
these analytes in both the control supernatants and the
LFA-1 MAb treated supernatants was below the limit of
detection of the assays (data not shown). Finally, we
broadened our search for the possible identity of the
soluble factor using an antibody array. This array was
used to test for the presence of 174 different analytes
including SDF-1, MDC, LIF, MCP-2, Lymphotactin, IL-8,
IL-10, IL-16, TGF-β and other common cytokines,
chemokines, and growth factors (for full list of analytes
see Additional file 1). Using this semi-quantitative
strategy, we identified a single analyte where the mean
signal intensity in LFA-1 MAb treated supernatants
was higher than the mean signal intensity in PBS
treated supernatants after subtracting out the signal
intensity of the media control. As shown in Figure 5B,
the mean signal intensity of Epidermal Growth Factor
(EGF) in LFA-1 MAb treated supernatants was 2241
relative units and significantly higher than the mean
signal intensity in PBS treated supernatants with a
mean of 1230 relative units (p=0.03, Wilcoxon sign
rank test). Using a quantitative ELISA for EGF, we were
unable to verify these results (Figure 5C). We, therefore,
conclude that the soluble factor induced by incubation
of cells with LFA-1 MAb is not one of the known HIV-1
inhibitory cytokines or chemokines. Furthermore, it is
not one of the common cytokines and chemokines we
tested for. This implies that LFA-1 MAb does not in-
duce any common immunomodulating cytokines and
chemokines.
Discussion
In this study, we set out to determine the in vitro mecha-
nisms of action of a monoclonal antibody that binds to
Lymphocyte Function-Associated Antigen-1 (LFA-1). We
found that LFA-1 MAb is able to bind HIV-1 virions and
preferentially binds to CD8+ T cells and dendritic cells.
When bound to virus, it does not inhibit HIV-1 replication
in culture. When bound to cells, it does not inhibit CTL
killing of activated uninfected CD4+ T cells, as was previ-
ously hypothesized; rather, it appears to induce the produc-
tion of an as yet unidentified soluble factor that can inhibit
HIV-1 replication.
Using a virus capture assay, we determined that LFA-1
MAb is able to bind to HIV-1. However, it does not ap-
pear to bind to CD4+ T cells. We know that LFA-1 takes
on different conformations based on the activation state
of a cell [16,17]. It is possible, that under specific condi-
tions, infected CD4+ T cells express LFA-1 in such a way
that LFA-1 MAb could bind. Indeed, others have shown
Figure 4 LFA-1 MAb induces the production of an anti-viral
soluble factor. PBMC from six HIV negative (open symbols) and
eight HIV-1 positive subjects (closed symbols) were incubated for 24
hours in the presence of increasing concentrations of LFA-1 MAb or
PBS alone (x-axis). Supernatant was harvested from these cultures
then mixed with fresh CD8-depleted PBMC and subsequently
infected with 10 TCID50 of HIV-SF162. The degree of viral replication
was measured on day 7 using a p24 ELISA. There was a significant
decrease in the mean concentration of p24 (indicated by the
horizontal line) in cultures containing LFA-1 MAb (p=0.0006, one
way ANOVA).
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in a CD4 dependent manner [18]. It has also been shown
that binding of α4β7 by gp120 results in an altered con-
formation of LFA-1 on CD4+ T cells [19]. It is therefore
possible that HIV-1 infection itself results in changes in
the conformation of LFA-1 on CD4+ T cells such that
they express the S6F1 epitope to which LFA-1 MAb
binds. Alternatively, LFA-1 MAb may only bind to the
virions that replicated within dendritic cells, which contain
L F A - 1o nt h e i rs u r f a c e .
Incubating PBMC with LFA-1 MAb for 24 hours
resulted in the production of a soluble factor that
inhibited HIV-1 replication. Given the cells that LFA-1
MAb binds and the short period of incubation, we hy-
pothesized that this factor was most likely a chemokine
or cytokine. However, we did not observe an increase
in the concentration of any of the analytes we tested in
supernatants from LFA-1 MAb exposed PBMC, as
compared to control. It is possible that a combination
of these factors may explain the anti-HIV-1 activity we
observed or that the antiviral soluble factor may vary
from one culture to another. This is difficult to assess
given the small number of cultures tested. Another pos-
sibility is that residual LFA-1 Mab in the supernatant
contributed to the inhibition we observed. However, we
did not observe inhibition of viral replication when
LFA-1 MAb is incubated with virus prior to infection.
It is also possible that this soluble factor is the same anti-
HIV-1 soluble factor, known as “CD8 Antiviral Factor”
(CAF). CAF is known to be produced by CD8+ T cells
[20]; however, it is typically produced after stimulation with
anti-CD3 antibodies and its production is maximized after
5–9 days of culture. Therefore, it seems unlikely that the
soluble factor is CAF. Further studies to identify the sol-
uble factor are warranted. Biochemical experiments to de-
termine it’s approximate size, it’s sensitivity to proteases,
and it’s tolerance to changes in pH and temperature may
yield important clues to its identity; however, ultimately it
may be necessary to isolate it from the complex mixture of
analytes in the cell culture supernatant and produce it in
sufficient quantities to get a definitive identification.
In this study, we have shown that LFA-1 MAb may be
able to inhibit HIV-1 replication as a result of binding to
either CD8+ Tcells or dendritic cells and inducing the pro-
duction of an antiviral soluble factor. This is just one of the
potential mechanisms by which this antibody could de-
crease HIV-1 replication in vivo. Other potential mecha-
nisms include interfering with cell-to-cell transmission of
virus or augmenting the HIV-1 specific immune response
by altering leukocyte trafficking. Additional studies are
needed to examine these mechanisms in more detail.
Our approach to identifying the antiviral soluble factor
does give us some insight into the impact that LFA-1
MAb may have on the immune system. Despite binding
Figure 5 Search for the identity of the anti-viral soluble factor. (A) Supernatants with anti-viral activity, obtained from culturing PBMC in the
presence of LFA-1 MAb, were tested for MIP1-alpha, MIP1-beta, and RANTES using a bead based ELISA assay. Results are expressed as the
concentration of each analyte in paired control and LFA-1 MAb treated supernatants. (B) Supernatants were then tested for the presence of 174
different analytes using a fluorescence based antibody array. Results from this semi-quantitative assay are expressed in relative light units.
Epidermal Growth Factor (EGF) was the only analyte where the signal intensity differed significantly between LFA-1 MAb treated and control
supernatants (p=0.0313). (C) To confirm this finding, the concentration of EGF was then determined by standard quantitative ELISA. Unless
noted, the difference between LFA-1 MAb and control treated supernatants were not significant.
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an immune response, we did not identify any chemokine
or cytokine that was produced as a consequence of the
interaction between LFA-1 MAb and LFA-1. Although
not shown here, we also did not observe an increase in
proliferation or apoptosis in cultures containing LFA-1
MAb. Thus, this antibody appears to have a benign ef-
fect, in general, on immune cells. This could be advanta-
geous if this antibody is further tested in human trials.
Conclusions
From this study we conclude that the mechanism of ac-
tion of LFA-1 MAb is not the result of the antibody bind-
ing to virus, but rather a downstream effect of it binding
to cells. Our data suggest that binding of LFA-1 MAb to
CD8+ T cells or dendritic cells may result in the produc-
tion of a yet-to-be-identified soluble antiviral factor.
Methods
Materials
Cytodyn Incorporated (Santa Fe, New Mexico) provided
the anti-LFA-1 monoclonal antibody (Cytolin
W). HIV-
SF162 and HIV-IIIB were obtained from the NIH AIDS
Reference and Reagent Program. These two viruses
were chosen because they utilize either CCR5 or
CXCR4 as a co-receptor for viral entry (SF162 and IIIB
respectively). HIV-AC225 is a primary isolate from a re-
cently infected individual. It is predicted to be a CCR5
utilizing isolate based on the sequence of the V3 region
of its envelope. All three viruses were propagated on
CD8-depleted PBMC from the same donor. Culture
media was prepared using RPMI supplemented with
Hepes, Penicillin/Streptomycin, L-glutamine, and 10%
fetal calf serum.
Subjects
Twenty-five subjects (13 HIV-1 negative and 12 HIV-1
positive) were enrolled in a blood draw only study. To
be included in the study, HIV-1 infected subjects had to
be in the asymptomatic stage of infection with a CD4 T
cell count greater than 350 cells/mm
3, an HIV-1 plasma
RNA viral load less than 100,000 copies/ml, and not be
on antiretroviral therapy. All subjects signed informed
consent as approved by the Massachusetts General Hos-
pital (MGH) Human Subjects Committee.
Peripheral blood samples were obtained by venipuncture
into tubes containing Acid Citrate Dextrose (ACD). Plasma
was separated from whole blood using centrifugation.
Peripheral blood mononuclear cells (PBMC) were obtained
by density gradient centrifugation (FICOLL, Sigma). HIV-1
serostatus was confirmed at the initial visit in all subjects.
T cell subset analysis was performed at every visit for all
subjects. HIV-1 RNA testing was performed at the initial
visit for all subjects, and then only for HIV-1 infected
subjects at subsequent visits. Assays were performed in the
Clinical Laboratory at MGH.
Virus capture
To determine whether LFA-1 MAb could bind to HIV-1, a
virus capture assay was performed similar to what has pre-
viously been described [21-23]. Briefly, ninety-six well
plates (Nunc) were coated with 5ug/ml of the anti-LFA-1
antibody, PBS, or 1 ug/ml mixture of monoclonal anti-
bodies specific to HIV-1 gp120, for 2 hours at room
temperature. The gp120-specific antibody mixture
contained three human monoclonal antibodies, 17b, A32,
and EH21. These antibodies bind to discontinuous epi-
topes, are known to cross-react with envelope glycopro-
teins from multiple Clade B isolates, and likely bind to
monomeric gp120 [24-27]. After blocking with PBS
containing 4% whey, undiluted virus stocks were plated in
triplicate, and incubated at room temperature for 2 hours.
Wells were washed with PBS containing 0.05% Tween20,
and harvested with 100ul PBS containing 0.5% TritonX
100. This supernatant was kept at 4°C overnight then di-
luted to 1:500 in PBS containing lysing solution. The pres-
ence of virus in these supernatants was determined using a
p24 ELISA, as per the manufacturers instructions (HIV-1
p24 ELISA, Zeptometrix).
Isolation of cell subsets
PBMC were depleted of CD8+ cells by magnetic bead
based separation using Dynabead CD8 (Invitrogen) as per
the manufacturers instructions. This resulted in >95%
depletion of CD8+ cells. CD4+ cells were isolated from
PBMC by positive selection using paramagnetic beads
coupled to anti-CD4 monoclonal antibodies (Dynabead
CD4, Invitrogen). This isolation was performed according
to the manufacturers instructions and resulted in a popula-
tion of cells containing >95% CD4+ cells.
CTL lysis of activated CD4+ T cells
To determine whether LFA-1 MAb abrogated CTL lysis
of activated uninfected CD4+ cells, we first obtained
CD4+ target cells using magnetic positive enrichment,
as described above. These cells were activated for three
days at 37°C with 1.25 ug/ml PHA (phytohemagglutinin)
in media containing 50U/ml IL-2. Autologous CD4+ cell
depleted PBMC were used as effector cells. These cells
were incubated with 10 ug/ml of LFA-1 MAb or PBS, as
a control, on ice for 30 minutes then added without
washing to the target cells. The activated CD4+ target
cells were differentiated from effector cells via staining
with 1uM CFSE. Effector and target cells were combined
at a ratio of 25:1. After a 4 hour co-culture at 37°C, all
cells were stained with 1 ug/ml 7AAD for 20 minutes at
room temperature. The cells were then washed in PBS
containing 2 ug/ml Actinomycin D and 1% fetal calf
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nomycin D containing buffer with 1% formaldehyde.
The frequency of CFSE + 7AAD +cells (dead targets)
was determined by flow cytometry on a BD LSRII. Single
stained controls were used to set the gates. Percent cyto-
toxicity was calculated using the following formula: 100*
(%sample lysis-%target cell only lysis)/(100-% target cell
only lysis).
Identifying cells that bind LFA-1 MAb
To determine the cell subsets that bind to this anti-LFA-1
antibody, flow cytometry was performed. PBMC were ei-
ther left inactivated or were activated for 1 hour at 37°C
with 10 ng/ml of PMA (phorbol 12-myristate 13-acetate)
and 5 ug/ml Ionomycin. The cells were then incubated
with 24 ug/ml of LFA-1 MAb for 20 minutes at 4°C. This
concentration of anti-LFA-1 was determined by titration
on PBMC using flow cytometry. After washing in PBS
containing 1% fetal calf serum, cells were stained with a
FITC-labeled anti-mouse IgG for 20 minutes at 4°C. The
various cell subsets were identified using fluorochrome-
labeled antibodies to discriminate T cells, B cells, mono-
cytes, and dendritic cells (CD3 PE, CD4 Q605, CD8
APC-Cy7, CD14 Pacific Blue, CD19 PE-Cy5, CD11c
APC). The cells were washed and fixed in 1% formalde-
hyde prior to acquisition on a BD LSR-II. Gating was
performed manually to identify CD3+ CD19- T cells,
CD19+ CD3- B cells, and CD19-CD3- monocytes and
dendritic cells. The T cell subset was further differenti-
ated into CD4+ and CD8+ cells. Dendritic cells were de-
fined as CD14- CD11c+, while monocytes were defined
as CD14+ CD11c+. The percent of LFA-1 MAb +cells
within each cell subset is reported.
Induction of soluble antiviral factors
To induce the production of an antiviral soluble factor,
ninety-six well round bottom plates (BD Falcon) were
coated with 1 ug/ml of LFA-1 MAb or PBS as a control
and stored up to 1 week at 4°C. On the day of the
assay, plates were warmed to room temperature and
2×10
5 PBMC were added to each well. After incuba-
tion at 37°C for 24 hours, the plates were centrifuged
at 1700 rpm for 7 minutes to pellet the cells and the
supernatant was removed and stored at −20°C prior to
use in subsequent assays.
HIV replication
To test the direct effect of LFA-1 MAb on HIV-1 repli-
cation, the antibody was incubated with virus then a
viral replication assay was performed. One hundred
TCID50 of each virus stock (HIV-SF162, HIV-IIB, HIV-
AC225) was incubated for 4 hours at 37°C with serial
10-fold dilutions of LFA-1 MAb. This mixture was then
used to infect CD8-depleted PBMC from a single HIV-1
negative donor that had been activated for 3 days with
1.25 ug/ml of PHA in RPMI supplemented with 50U IL-2.
Infected cells were maintained at 37°C for 7 days. The de-
gree of viral replication was determined by measuring
the concentration of p24 in the supernatant using an
ELISA, as per the manufacturers instructions (HIV-1
p24 ELISA, Zeptometrix).
To test the effect of induced soluble factors on HIV-1
replication, a viral replication assay was performed in
the presence of supernatant from PBMC treated with
LFA-1 MAb or PBS, as described above. PHA activated
CD8-depleted PBMC from a single HIV-1 negative donor
were resuspended in supernatants diluted 1:2 with culture
media, then infected with 10 TCID50 of HIV-SF162 and
incubated at 37°C for 7 days. The concentration of p24
was then measured using an ELISA as per the manufac-
turers instructions (HIV-1 p24 ELISA, Zeptometrix).
Chemokines
Several assays were used in an attempt to determine
the identity of the soluble factor. We started by testing
for the presence of cytokines and chemokines that are
known to have anti-HIV activity. The concentrations
of MIP1-alpha, MIP1-beta, and RANTES were deter-
mined using a multiplex bead based ELISA system
(Flowcytomix, Bender). Twenty-five microliters of super-
natant from PBMC cultures incubated with either LFA-1
MAb or PBS (see above) were mixed with antibody-labeled
beads, and biotin-conjugated secondary antibodies. After
2-hours of incubation, the beads were pelleted by centri-
fugation and incubated with PE-Streptavidin for 1 hour.
The beads were then washed and resuspended in assay
buffer containing 1% formaldehyde to ensure the sam-
ples were not infectious. Preliminary experiments verified
that the use of formaldehyde did not interfere with the
measurement of the analytes. The fluorescent signal
from the beads was detected using a BD LSR-II flow
cytometer. The resulting data was analyzed using the
Flowcytomix software provided by the manufacturer.
The concentration of each chemokine was determined
by comparison to a standard curve generated from re-
combinant chemokines provided by the manufacturer.
An ELISA was performed to determine the concentra-
tion of alpha-defensins 1, 2 and 3 (Human HNP 1–3,
Hycult Biotech) and Interferon-alpha (Human IFN-alpha
pan ELISA kit, MAbtech). One hundred microliters of
supernatant from PBMC cultures incubated with LFA-1
MAb or PBS were diluted 1:2 in dilution buffer and the
assay was performed in duplicate according to each
manufacturer’s instructions. The captured analytes were
detected using a biotinylated secondary detection
antibody followed by Streptavidin-peroxidase, and de-
veloped using a TMB substrate. Serial dilutions of
the standards provided by each manufacturer were
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which the concentration of alpha defensins or IFN-
alpha was calculated.
To broaden our search for the identity of the soluble
factor, we utilized an antibody array (G2000 Human
Cytokine Array, RayBioTech). This assay is similar to a
standard sandwich ELISA, but it is performed on a
glass slide and utilizes a fluorescent readout. This array
can detect 174 different analytes including common cy-
tokines, chemokines, and growth factors. A full list of
the analytes can be found in Additional file 1. Super-
natant from PBMC cultures incubated with either LFA-1
MAb or PBS (see above) was sent to RayBiotech for
testing. Since the cell culture media we used in this
assay contained serum, which includes many of the
analytes being measured, a media only control was
also tested. The mean signal intensity of LFA-1 MAb
treated supernatants was compared to the mean signal
intensity of PBS treated supernatants after subtracting
out the signal intensity of the media control. A Wilcoxon
sign rank test was used to determine whether the mean
signal intensity was higher in LFA-1 MAb treated
supernatants.
A follow-up experiment was performed to determine
the concentration of Epidermal Growth Factor (EGF) in
the LFA-1 MAb and PBS treated supernatants. In this
quantitative ELISA, 100ul of supernatant was diluted 1:2
in dilution buffer and the assay was performed in dupli-
cate as indicated by the manufacturer (EGF Human
ELISA kit, MAbtech). Duplicate wells of serial dilutions
the EGF standard were run in parallel with the samples
to generate a standard curve from which the concentra-
tion of EGF was calculated.
Additional file
Additional file 1: Table S1. RLU = Relative Light Units. Data shown are
the mean signal intensity for each analyte of PBS and Cytolin treated
supernatants after subtracting out the signal intensity of the media
control. *Unless otherwise indicated, the mean signal intensity in Cytolin
treated supernatants was not significantly higher than in control treated
supernatants.
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